Individual prognoses of long-term responses to antiretroviual treatment based on virological, immunological and pharmacological parameters measured during the first week under therapy

AIDS

Volumn 12, Issue 15, 1998, Pages

  Mueller, Brigitta U ^a,d   Zeichner, Steven L ^a   Kuznetsov, Vladimir A ^b,e   Heath Chiozzi, Margo ^c   Pizzo, Philip A ^a,d   Dimitrov, Dimiter S ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c ABBOTT LABORATORIES   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e EMANUEL INSTITUTE OF BIOCHEMICAL PHYSICS   (Russian Federation)

Author keywords

Antiretroviral therapy; HIV 1; Pediatrics; Prognosis

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; RITONAVIR; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL PARAMETERS; LYMPHOCYTE COUNT; PHARMACOLOGICAL PARAMETERS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

EID: 0032558754     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199815000-00004     Document Type: Article

References (12)

1. Mellors JW, Rinaldo Jr CR, Gupta P, White RM, Todd JA, Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
2. Palumbo PF, Raskino C, Fiscus S, et al.: Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA 1998, 279:756-761.
3. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997, 126:946-954.
4. Katzenstein DA, Hammer SM, Hughes MD, et al.: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 1996, 335:1091-1098.
5. + lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med 1996, 334:426-431.
6. + lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS. Ann Intern Med 1997, 126:939-945.
7. + lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med 1997, 126:929-938.
8. Mueller BU, Nelson RPJ, Sleasman J, et al.: A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection. Pediatrics 1998, 101:335-343.
9. Dimitrov DS: Modeling of HIV infection. In: Computer Modeling and Simulation of Complex Biological Systems. Edited by Iyengar SS, Boca Raton: CRC Press; 1998:79-100.
10. Kuznetsov VA, Ivshina AV, Senko OV, Kuznetsova AV: Syndrome approach for computer recognition of fuzzy systems and its application to immunological diagnostics and prognosis of human cancer. Math Comp Modeling 1996, 23:95-119.
11. Jackson AM, Ivshina AV, Senko O, et al.: Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis. J Urol 1998, 159:1054-1063.
12. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1586.